Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $3.43 billion
- Book Value:
- Revenue TTM:
- $350.40 million
- Operating Margin TTM:
- Gross Profit TTM:
- $227.70 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Abcam PLC had its IPO on 2010-12-03 under the ticker symbol ABCM.
The company operates in the Healthcare sector and Biotechnology industry. Abcam PLC has a staff strength of 1,682 employees.
Shares of Abcam PLC opened at $16.34 at the start of the last trading session i.e. 2023-06-02.
The stocks traded within a range of $16.31 - $17.05, and closed at $16.9.
This is a +4% increase from the previous day's closing price.
A total volume of 1,340,463 shares were traded at the close of the day’s session.
In the last one week, shares of Abcam PLC have increased by +0.6%.
Abcam PLC's Key Ratios
Abcam PLC has a market cap of $3.43 billion, indicating a price to book ratio of 4.0028 and a price to sales ratio of 10.2269.
In the last 12-months Abcam PLC’s revenue was $350.40 million with a gross profit of $227.70 million and an EBITDA of $77.30 million. The EBITDA ratio measures Abcam PLC's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Abcam PLC’s operating margin was 14.61% while its return on assets stood at 3.26% with a return of equity of 0.69%.
In Q2, Abcam PLC’s quarterly earnings growth was a positive 95.1% while revenue growth was a positive 23.3%.
Abcam PLC’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $0.08 per share while it has a forward price to earnings multiple of 31.5457 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Abcam PLC’s profitability.
Abcam PLC stock is trading at a EV to sales ratio of 11.6931 and a EV to EBITDA ratio of 77.8063. Its price to sales ratio in the trailing 12-months stood at 10.2269.
Abcam PLC stock pays annual dividends of $0 per share, indicating a yield of 0.75% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $1.06 billion
- Total Liabilities
- $203.80 million
- Operating Cash Flow
- Capital Expenditure
- $2.25 million
- Dividend Payout Ratio
Abcam PLC ended 2023 with $1.06 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.06 billion while shareholder equity stood at $727.60 million.
Abcam PLC ended 2023 with $0 in deferred long-term liabilities, $203.80 million in other current liabilities, 500000.00 in common stock, $304.40 million in retained earnings and $397.90 million in goodwill. Its cash balance stood at $109.60 million and cash and short-term investments were $109.60 million. The company’s total short-term debt was $133,400,000 while long-term debt stood at $0.
Abcam PLC’s total current assets stands at $257.80 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $72.10 million compared to accounts payable of $56.70 million and inventory worth $57.50 million.
In 2023, Abcam PLC's operating cash flow was $-6950000.00 while its capital expenditure stood at $2.25 million.
Comparatively, Abcam PLC paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Abcam PLC stock is currently trading at $16.9 per share. It touched a 52-week high of $19.39 and a 52-week low of $19.39. Analysts tracking the stock have a 12-month average target price of $18.65.
Its 50-day moving average was $15.6 and 200-day moving average was $15.41 The short ratio stood at 0.64 indicating a short percent outstanding of 0%.
Around 1.1% of the company’s stock are held by insiders while 7927.2% are held by institutions.
Frequently Asked Questions About Abcam PLC
Similar Industry Stocks (Biotechnology)
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools. The company serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. It has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. The company sells its products online. Abcam plc was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom.